ALKS insider trading
HealthcareAlkermes plc.: insider trade history from SEC Form 4 filings.
About Alkermes plc.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Company website: www.alkermes.com
ALKS insider activity at a glance
FilingIQ tracks 1,747 insider transactions for ALKS in filings since Jan 5, 2015. The most recent transaction is dated Oct 2, 2026.
Across the full history, 8 open-market purchases
and 426 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ALKS insider trades is 59.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ALKS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading ALKS
13F funds holding ALKS
Frequently asked
- How many insider trades does FilingIQ track for ALKS?
- FilingIQ tracks 1,747 Form 4 insider transactions for ALKS (Alkermes plc.), covering filings from Jan 5, 2015 onwards. 13 of those are dated within the last 90 days.
- Are ALKS insiders net buyers or net sellers?
- Across the full Form 4 history for ALKS, 8 transactions (0%) were open-market purchases and 426 (24%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ALKS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ALKS in?
- Alkermes plc. (ALKS) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $5.48B.
Methodology & sources
Every ALKS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.